Primecap Management Co holds a diversified book of 320 stocks worth $127.0B as of Q1 2026 (disclosed May 11, 2026, a ~41-day 13F lag). This quarter they opened AstraZeneca PLC and trimmed Eli Lilly & Co. Their largest long position is Eli Lilly & Co at 7% of the equity book. Cloning the disclosed picks since 2013 would be +477% (+14.7%/yr). That is a simulation of the disclosed long book, not audited returns.
The reported book (valued from quarter-end) returned +502.8%, a 25.8-point gap that is the cost of the ~41-day 13F disclosure lag a real follower can't avoid.
Growth of $10,000 cloning Primecap Management Co's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~41 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Primecap Management Co
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 80 / 80 | $2.1T |
| STATE STREET CORP | 80 / 80 | $1.4T |
| FMR LLC | 80 / 80 | $776.8B |
| MORGAN STANLEY | 80 / 80 | $461.7B |
| JPMORGAN CHASE & CO | 80 / 80 | $445.8B |
| NORTHERN TRUST CORP | 80 / 80 | $280.5B |
| BANK OF AMERICA CORP /DE/ | 80 / 80 | $273.4B |
| GOLDMAN SACHS GROUP INC | 80 / 80 | $219.6B |
Ranked by how many of Primecap Management Co's top 80 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Eli Lilly & Co COM | $8.5B | 9.22M | 6.7% | ▼−0.5% Reduced · −42K sh | |
| 2 | Micron Technology Inc COM | $7.4B | 21.87M | 5.8% | ▼−12% Reduced · −2.9M sh | |
| 3 | Alphabet Inc CAP STK CL A | $4.3B | 14.99M | 3.4% | ▼−0.9% Reduced · −141K sh | |
| 4 | AstraZeneca PLC ORD | $3.6B | 18.21M | 2.8% | ▲New New position | |
| 5 | Kla Corp COM NEW | $3.6B | 2.44M | 2.8% | ▼−15% Reduced · −438K sh | |
| 6 | Intel Corp COM | $3.3B | 75.76M | 2.6% | ▼−0.5% Reduced · −370K sh | |
| 7 | Amgen Inc COM | $3.1B | 8.87M | 2.5% | ▼−0.3% Reduced · −31K sh | |
| 8 | Nvidia Corporation COM | $3.0B | 17.19M | 2.4% | ▼−0.2% Reduced · −39K sh | |
| 9 | Fedex Corp COM | $3.0B | 8.30M | 2.3% | ▼−2.5% Reduced · −210K sh | |
| 10 | Biogen Inc COM | $2.7B | 14.76M | 2.1% | ▼~0% Reduced · −390 sh | |
| 11 | Microsoft Corp COM | $2.7B | 7.26M | 2.1% | ▼−0.3% Reduced · −23K sh | |
| 12 | Amazon Com Inc COM | $2.5B | 12.11M | 2.0% | ▼−1.2% Reduced · −149K sh | |
| 13 | Alibaba Group Hldg Ltd SPONSORED ADS | $2.3B | 18.72M | 1.8% | ▼−1.3% Reduced · −255K sh | |
| 14 | Tesla Inc COM | $2.3B | 6.13M | 1.8% | ▼−3.0% Reduced · −192K sh | |
| 15 | Schwab Charles Corp COM | $2.2B | 23.44M | 1.7% | ▲+0.7% Added · +166K sh | |
| 16 | Boston Scientific Corp COM | $2.0B | 32.53M | 1.6% | ▲+4.6% Added · +1.4M sh | |
| 17 | Ross Stores Inc COM | $2.0B | 9.17M | 1.6% | ▼−0.4% Reduced · −37K sh | |
| 18 | Texas Instrs Inc COM | $1.9B | 9.65M | 1.5% | ▼−4.3% Reduced · −430K sh | |
| 19 | Southwest Airls Co COM | $1.8B | 47.07M | 1.4% | ▼−0.7% Reduced · −323K sh | |
| 20 | Flextronics Intl Ltd ORD | $1.7B | 25.38M | 1.3% | ▼−4.9% Reduced · −1.3M sh | |
| 21 | Alphabet Inc CAP STK CL C | $1.6B | 5.72M | 1.3% | ▼−0.7% Reduced · −42K sh | |
| 22 | TJX Cos Inc New COM | $1.5B | 9.59M | 1.2% | ▼−1.5% Reduced · −150K sh | |
| 23 | ConocoPhillips COM | $1.5B | 11.58M | 1.2% | ▲~0% Added · +2K sh | |
| 24 | Bristol-Myers Squibb Co COM | $1.5B | 24.99M | 1.2% | ▲+0.4% Added · +110K sh | |
| 25 | Beone Medicines Ltd SPONSORED ADS | $1.5B | 4.98M | 1.2% | ▼−0.1% Reduced · −5K sh | |
| 26 | United Airls Hldgs Inc COM | $1.5B | 15.75M | 1.1% | ▼−1.4% Reduced · −228K sh | |
| 27 | GSK PLC SPONSORED ADR | $1.4B | 25.20M | 1.1% | ▲+0.3% Added · +74K sh | |
| 28 | Raymond James Finl Inc COM | $1.4B | 9.35M | 1.1% | ▲+0.1% Added · +5K sh | |
| 29 | Baidu Inc SPON ADR REP A | $1.2B | 11.06M | 1.0% | ▼−0.4% Reduced · −47K sh | |
| 30 | Visa Inc COM CL A | $1.2B | 4.06M | 1.0% | ▲+1.3% Added · +51K sh | |
| 31 | Sony Group Corp SPONSORED ADR | $1.2B | 58.53M | 1.0% | ▲+0.4% Added · +229K sh | |
| 32 | Delta Air Lines Inc COM NEW | $1.2B | 17.55M | 0.9% | ▼−0.3% Reduced · −46K sh | |
| 33 | Novartis AG SPONSORED ADR | $1.2B | 7.57M | 0.9% | ▼−0.1% Reduced · −12K sh | |
| 34 | Adobe Inc COM | $1.1B | 4.73M | 0.9% | ▲+29% Added · +1.1M sh | |
| 35 | Elanco Animal Health Inc COM | $1.1B | 45.84M | 0.9% | ▼−0.8% Reduced · −373K sh | |
| 36 | JPMorgan Chase & Co COM | $1.0B | 3.40M | 0.8% | ▼−5.6% Reduced · −203K sh | |
| 37 | Analog Devices Inc COM | $997.7M | 3.14M | 0.8% | ▼−0.2% Reduced · −6K sh | |
| 38 | Thermo Fisher Scientific Inc COM | $974.5M | 1.98M | 0.8% | ▼−3.6% Reduced · −75K sh | |
| 39 | Netapp Inc COM | $927.4M | 9.06M | 0.7% | ▼−0.1% Reduced · −11K sh | |
| 40 | Northern TR Corp COM | $914.0M | 6.55M | 0.7% | ▼−0.9% Reduced · −59K sh | |
| 41 | Jabil Inc COM | $871.6M | 3.28M | 0.7% | ▼−1.9% Reduced · −63K sh | |
| 42 | Oracle Corp COM | $834.7M | 5.67M | 0.7% | ▼−5.9% Reduced · −358K sh | |
| 43 | Nextpower Inc CLASS A COM | $815.0M | 6.76M | 0.6% | ▼−2.7% Reduced · −191K sh | |
| 44 | Biomarin Pharmaceutical Inc COM | $801.8M | 14.19M | 0.6% | ▼−2.4% Reduced · −355K sh | |
| 45 | AECOM COM | $733.4M | 8.65M | 0.6% | ▼−0.2% Reduced · −20K sh | |
| 46 | Royal Caribbean Group COM | $645.8M | 2.35M | 0.5% | ▼−2.6% Reduced · −64K sh | |
| 47 | Idex Corp COM | $626.1M | 3.30M | 0.5% | ▲+2.4% Added · +76K sh | |
| 48 | Caterpillar Inc COM | $618.0M | 872.3K | 0.5% | ▼−0.9% Reduced · −8K sh | |
| 49 | Wells Fargo & Co COM | $614.8M | 7.72M | 0.5% | ▼−7.6% Reduced · −637K sh | |
| 50 | Disney Walt Co COM | $600.9M | 6.24M | 0.5% | ▼~0% Reduced · −2K sh |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/763212/holdings"
Use Arkolith to show PRIMECAP MANAGEMENT CO/CA/'s latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 11, 2026 | 320 | $127.0B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 11, 2026 | 319 | $132.1B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 12, 2025 | 327 | $130.6B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 11, 2025 | 333 | $126.2B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 9, 2025 | 335 | $121.0B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 10, 2025 | 329 | $129.1B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 8, 2024 | 336 | $136.0B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 9, 2024 | 332 | $138.1B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 14, 2024 | 335 | $134.1B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 9, 2024 | 334 | $126.3B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 13, 2023 | 331 | $118.5B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 11, 2023 | 328 | $119.7B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 331 | $114.7B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 13, 2023 | 334 | $109.2B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 335 | $103.3B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 11, 2022 | 341 | $111.9B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 11, 2022 | 339 | $132.6B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 11, 2022 | 342 | $144.5B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 12, 2021 | 337 | $141.7B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 10, 2021 | 333 | $148.8B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 14, 2021 | 327 | $143.4B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 8, 2021 | 319 | $134.5B | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 13, 2020 | 311 | $121.2B | 13F-HR |
| Q2 2020 | Jun 30, 2020 | Aug 13, 2020 | 306 | $116.5B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.